Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AHK-Cu and LL-37 — mechanism, side effects, legal status, and pricing.
AHK-Cu is a copper-binding tripeptide (Ala-His-Lys-Cu) structurally related to GHK-Cu, studied in dermatological research for its role in extracellular matrix remodeling and hair follicle signaling.
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide (starting with two leucines) cleaved from the hCAP-18 precursor. It has broad-spectrum antimicrobial activity and immunomodulatory roles, but is also implicated in the pathogenesis of autoimmune and inflammatory skin diseases including psoriasis, rosacea, and lupus. Not FDA-approved; research-use only.
AHK-Cu
LL-37
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AHK-Cu
LL-37
COA corpus from Disclosed Labs — independently tested batches only.
AHK-Cu
14
COAs
99.6%
Avg purity
5
Labs
LL-37
31
COAs
99.2%
Avg purity
8
Labs
Pyo et al. (Archives of Pharmacal Research, 2007) reported that AHK-Cu stimulated elongation of human hair follicles ex vivo, promoted proliferation of dermal papilla cells, and increased VEGF secretion while reducing TGF-beta1 in cultured fibroblasts. Evidence is preclinical only; no controlled clinical trials have been published.
LL-37 was characterized in the mid-1990s as the processed antimicrobial product of hCAP-18 (Gudmundsson et al., 1996). Dürr et al. (2006, Biochim Biophys Acta, PMID 16716248) provided a foundational review of its structure and activity as the sole human cathelicidin. Overhage et al. (2008, Infection and Immunity, PMID 18591225) showed LL-37 prevents Pseudomonas aeruginosa biofilm formation at 0.5 µg/mL — far below its MIC. A randomized, placebo-controlled Phase 1/2 trial (Grönberg et al., 2014, Wound Repair and Regeneration, PMID 25041740) found topical LL-37 safely accelerated healing of hard-to-heal venous leg ulcers at low doses. Its dual role in autoimmunity is well established: Lande et al. (2014, Nature Communications, PMID 25470744) identified LL-37 as a T-cell autoantigen in two-thirds of moderate-to-severe plaque psoriasis patients. No FDA approval exists for any indication. Injectable grey-market protocols for Lyme, biofilm, or mold illness lack controlled clinical evidence and carry theoretical autoimmune risk given LL-37's role in psoriasis, lupus, and rosacea pathogenesis.
Key references
AHK-Cu (Cosmetic) and LL-37 (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs